Literature DB >> 16114891

Impact of the C-terminal domain of topoisomerase IIalpha on the DNA cleavage activity of the human enzyme.

Jennifer S Dickey1, Neil Osheroff.   

Abstract

The enzymatic function of the C-terminal domain of eukaryotic topoisomerase II is not well defined. This region of the enzyme is highly variable and hydrophilic and contains nuclear localization signals and phosphorylation sites. In contrast to eukaryotic topoisomerase II, type II enzymes from chlorella virus completely lack the C-terminal domain. These viral enzymes are characterized by a robust DNA cleavage activity, high coordination between their two active site tyrosyl residues, and reduced sensitivity to anticancer drugs. As a first step toward characterizing the contribution of the C-terminal domain of human topoisomerase IIalpha to enzyme function, the protein was truncated at amino acid 1175, which corresponds to the C-terminal residue of Paramecium bursaria chlorella virus-1 topoisomerase II as determined by BLAST sequence alignment. Although the overall catalytic activity of the resulting enzyme, hTop2alphaDelta1175, was lower than that of full-length topoisomerase IIalpha, the mutant protein displayed a double-stranded DNA cleavage activity that was approximately 2-3-fold higher. While the DNA breaks created by hTop2alphaDelta1175 were primarily double stranded, cuts generated by topoisomerase IIalpha were primarily single stranded. Thus, the enhanced cleavage observed for hTop2alphaDelta1175 appears to be due, at least in part, to an increase in active site coordination. Finally, hTop2alphaDelta1175 displayed a distinctly lower susceptibility to anticancer agents than did topoisomerase IIalpha, despite the fact that it showed a similar binding affinity for etoposide. Therefore, the C-terminal domain of human topoisomerase IIalpha appears to play significant roles in modulating the DNA cleavage/ligation reaction of the enzyme and its response to anticancer agents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16114891      PMCID: PMC2678941          DOI: 10.1021/bi050811l

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  54 in total

Review 1.  Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.

Authors:  J M Fortune; N Osheroff
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2000

2.  DNA topoisomerase IIbeta and neural development.

Authors:  X Yang; W Li; E D Prescott; S J Burden; J C Wang
Journal:  Science       Date:  2000-01-07       Impact factor: 47.728

Review 3.  DNA topoisomerases: structure, function, and mechanism.

Authors:  J J Champoux
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

4.  C-terminal domain of gyrase A is predicted to have a beta-propeller structure.

Authors:  Yuan Qi; Jimin Pei; Nick V Grishin
Journal:  Proteins       Date:  2002-05-15

5.  MLL-SEPTIN6 fusion recurs in novel translocation of chromosomes 3, X, and 11 in infant acute myelomonocytic leukaemia and in t(X;11) in infant acute myeloid leukaemia, and MLL genomic breakpoint in complex MLL-SEPTIN6 rearrangement is a DNA topoisomerase II cleavage site.

Authors:  Diana J Slater; Eva Hilgenfeld; Eric F Rappaport; Narayan Shah; Rita G Meek; Wendy Reed Williams; Brian D Lovett; Neil Osheroff; Reshma S Autar; Thomas Ried; Carolyn A Felix
Journal:  Oncogene       Date:  2002-07-11       Impact factor: 9.867

6.  Topoisomerase II from Chlorella virus PBCV-1 has an exceptionally high DNA cleavage activity.

Authors:  J M Fortune; O V Lavrukhin; J R Gurnon; J L Van Etten; R S Lloyd; N Osheroff
Journal:  J Biol Chem       Date:  2001-04-25       Impact factor: 5.157

7.  Co-localization of chicken DNA topoisomerase IIalpha, but not beta, with sites of DNA replication and possible involvement of a C-terminal region of alpha through its binding to PCNA.

Authors:  A Niimi; N Suka; M Harata; A Kikuchi; S Mizuno
Journal:  Chromosoma       Date:  2001-05       Impact factor: 4.316

Review 8.  Leukemias related to treatment with DNA topoisomerase II inhibitors.

Authors:  C A Felix
Journal:  Med Pediatr Oncol       Date:  2001-05

9.  Site-specific DNA cleavage by Chlorella virus topoisomerase II.

Authors:  John M Fortune; Jennifer S Dickey; Oleg V Lavrukhin; James L Van Etten; R Stephen Lloyd; Neil Osheroff
Journal:  Biochemistry       Date:  2002-10-01       Impact factor: 3.162

10.  A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents.

Authors:  Erin K O'Reilly; Kenneth N Kreuzer
Journal:  Biochemistry       Date:  2002-06-25       Impact factor: 3.162

View more
  27 in total

1.  Probing conformational changes in human DNA topoisomerase IIα by pulsed alkylation mass spectrometry.

Authors:  Yu-Tsung Chen; Tammy R L Collins; Ziqiang Guan; Vincent B Chen; Tao-Shih Hsieh
Journal:  J Biol Chem       Date:  2012-06-07       Impact factor: 5.157

2.  SUMOylation of the C-terminal domain of DNA topoisomerase IIα regulates the centromeric localization of Claspin.

Authors:  Hyunju Ryu; Makoto M Yoshida; Vinidhra Sridharan; Akiko Kumagai; William G Dunphy; Mary Dasso; Yoshiaki Azuma
Journal:  Cell Cycle       Date:  2015-07-01       Impact factor: 4.534

3.  6,6'-Dihydroxythiobinupharidine as a poison of human type II topoisomerases.

Authors:  Esha D Dalvie; Jacob Gopas; Avi Golan-Goldhirsh; Neil Osheroff
Journal:  Bioorg Med Chem Lett       Date:  2019-06-04       Impact factor: 2.823

Review 4.  Molecular mechanisms of topoisomerase 2 DNA-protein crosslink resolution.

Authors:  Amanda A Riccio; Matthew J Schellenberg; R Scott Williams
Journal:  Cell Mol Life Sci       Date:  2019-11-15       Impact factor: 9.261

Review 5.  SUMO modification of DNA topoisomerase II: trying to get a CENse of it all.

Authors:  Ming-Ta Lee; Jeff Bachant
Journal:  DNA Repair (Amst)       Date:  2009-02-20

6.  Bimodal recognition of DNA geometry by human topoisomerase II alpha: preferential relaxation of positively supercoiled DNA requires elements in the C-terminal domain.

Authors:  A Kathleen McClendon; Amanda C Gentry; Jennifer S Dickey; Marie Brinch; Simon Bendsen; Anni H Andersen; Neil Osheroff
Journal:  Biochemistry       Date:  2008-12-16       Impact factor: 3.162

7.  Chiral discrimination and writhe-dependent relaxation mechanism of human topoisomerase IIα.

Authors:  Yeonee Seol; Amanda C Gentry; Neil Osheroff; Keir C Neuman
Journal:  J Biol Chem       Date:  2013-03-18       Impact factor: 5.157

Review 8.  DNA topoisomerase II, genotoxicity, and cancer.

Authors:  A Kathleen McClendon; Neil Osheroff
Journal:  Mutat Res       Date:  2007-07-03       Impact factor: 2.433

9.  Coordinating the two protomer active sites of human topoisomerase IIalpha: nicks as topoisomerase II poisons.

Authors:  Joseph E Deweese; Neil Osheroff
Journal:  Biochemistry       Date:  2009-02-24       Impact factor: 3.162

10.  Granzyme M targets topoisomerase II alpha to trigger cell cycle arrest and caspase-dependent apoptosis.

Authors:  S A H de Poot; K W Lai; L van der Wal; K Plasman; P Van Damme; A C Porter; K Gevaert; N Bovenschen
Journal:  Cell Death Differ       Date:  2013-11-01       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.